0
Skip to Content
RApport
🔍 Search
Stories
All Stories
All Biotech
All Planetary Health
Culture
Finance
Policy
Science
About
Resources
Disclosure
SUBSCRIBE
RApport
🔍 Search
Stories
All Stories
All Biotech
All Planetary Health
Culture
Finance
Policy
Science
About
Resources
Disclosure
SUBSCRIBE
🔍 Search
Folder: Stories
Back
All Stories
All Biotech
All Planetary Health
Culture
Finance
Policy
Science
About
Resources
Disclosure
SUBSCRIBE

Science

Policy

Culture

Finance

Rational design of molecular glues - the next frontier
Science, Biotech Chris Morrison 10/12/21 Science, Biotech Chris Morrison 10/12/21

Rational design of molecular glues - the next frontier

As more established targeted protein degradation companies produce promising data in the clinic, newcomers have been greeted with sustained enthusiasm from the investment community. Here we revisit a few key intellectual and scientific breakthroughs & focus on molecular glues as an exciting new frontier.

Read More
Innovation thrives in the spotlight
Culture, Science, Biotech Thomas Culman 9/29/21 Culture, Science, Biotech Thomas Culman 9/29/21

Innovation thrives in the spotlight

The story of Alexander Fleming is a popular one. As it should be - it’s a good story about one of the most important discoveries in medical history, penicillin. But most people only know the first act of the play.

Read More
RA TV: Past, present, & future
Science, Biotech Thomas Culman 9/13/21 Science, Biotech Thomas Culman 9/13/21

RA TV: Past, present, & future

In this month’s episode of RA TV, we look back at the past year for biotech, examine today’s headlines, and contemplate the future of this pandemic — and maybe the next one.

Read More
And now for something completely different
Culture, Science, Biotech Chris Morrison 9/9/21 Culture, Science, Biotech Chris Morrison 9/9/21

And now for something completely different

LENZ Therapeutics CEO Eef Schimmelpennink spoke with RApport about how last year’s acquisition of Pfenex by Ligand gave him a chance to seek out a new challenge, the benefits of breaking the mold, and helping 120 million Americans ditch their reading glasses.

Read More
RA TV: Aduhelm &amp; Patient-Centered Healthcare Reforms</a>
Policy, Science, Biotech Guest User 8/26/21 Policy, Science, Biotech Guest User 8/26/21

RA TV: Aduhelm & Patient-Centered Healthcare Reforms

Listen in as RA Capital’s TechAtlas Associates convene to discuss recent Covid-19 news. Learn about the emerging Delta variant, new data from Novavax and CureVac, and the potential association between mRNA vaccines and myocarditis.

Read More
Accelerating life science tools R&amp;D with venture studios
Finance, Culture, Science, Biotech Chris Morrison 7/22/21 Finance, Culture, Science, Biotech Chris Morrison 7/22/21

Accelerating life science tools R&D with venture studios

Interest in life science technologies and tools is accelerating with the advent of CRISPR and other aspects of synthetic biology. The ability to have a capital efficient way to advance these innovations is very attractive and will help drive innovation.

Read More
RA TV: Vaccines versus variants
Science, Biotech Guest User 7/8/21 Science, Biotech Guest User 7/8/21

RA TV: Vaccines versus variants

Listen in as RA Capital’s TechAtlas Associates convene to discuss recent Covid-19 news. Learn about the emerging Delta variant, new data from Novavax and CureVac, and the potential association between mRNA vaccines and myocarditis.

Read More
It’s time to bring generic drug manufacturing back to the U.S.
Policy, Science, Biotech Peter Kolchinsky 6/2/20 Policy, Science, Biotech Peter Kolchinsky 6/2/20

It’s time to bring generic drug manufacturing back to the U.S.

Repatriating the American drug supply is key not just to averting shortages but to restoring and preserving the integrity of generic drugs in America.

Read More
Newer Posts
RAPPORT_PRIMARY_LOGO_Full_72.png

Home

Stories

About

Contact

Disclosure

© Copyright 2001-2025 RA Capital Management, L.P. This website is for informational purposes only and does not constitute an offer to provide investment advisory or other services by RA Capital Management, L.P. (“RA Capital”). Nothing contained on the website constitutes investment advice, and the views expressed should not be taken as advice to buy, sell, or hold any security or as an endorsement of any security or company. In preparing the information contained in this website, RA Capital has not taken into account the investment needs, objectives, and financial circumstances of any particular investor, and investments and companies referenced may not be suitable for all investors. Any views expressed were prepared based upon information available and believed to be reliable at the time such views were written. RA Capital makes no guarantees as to their accuracy or completeness. All information is subject to change and may quickly become unreliable for various reasons, including changes in market conditions or economic circumstances. By accessing this website, you agree not to copy, reproduce, republish, upload, post, transmit, alter, or distribute, in any way, content or materials from this website in any manner inconsistent with the purposes for which it is offered without the prior written consent of RA Capital.
Tweets by rapport_bio